126 related articles for article (PubMed ID: 1329443)
1. Stimulation of host-defense mechanism with synthetic adjuvants and recombinant cytokines against viral infection in mice.
Azuma I; Ishihara C; Iida J; Yoo YC; Yoshimatsu K; Arikawa J
Adv Exp Med Biol; 1992; 319():253-63. PubMed ID: 1329443
[TBL] [Abstract][Full Text] [Related]
2. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
[TBL] [Abstract][Full Text] [Related]
4. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogues.
Saiki I; Saito S; Fujita C; Ishida H; Iida J; Murata J; Hasegawa A; Azuma I
Vaccine; 1988 Jun; 6(3):238-44. PubMed ID: 2844032
[TBL] [Abstract][Full Text] [Related]
6. Protective activity of recombinant cytokines against Sendai virus and herpes simplex virus (HSV) infections in mice.
Iida J; Saiki I; Ishihara C; Azuma I
Vaccine; 1989 Jun; 7(3):229-33. PubMed ID: 2476892
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.
Azuma I; Otani T
Med Res Rev; 1994 Jul; 14(4):401-14. PubMed ID: 8084203
[No Abstract] [Full Text] [Related]
8. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
[TBL] [Abstract][Full Text] [Related]
9. Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice.
Ishihara C; Mizukoshi N; Iida J; Kato K; Yamamoto K; Azuma I
Vaccine; 1987 Dec; 5(4):295-301. PubMed ID: 2448969
[TBL] [Abstract][Full Text] [Related]
10. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
[TBL] [Abstract][Full Text] [Related]
12. Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl- L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice.
Ishihara C; Iida J; Mizukoshi N; Yamamoto N; Yamamoto K; Kato K; Azuma I
Vaccine; 1989 Aug; 7(4):309-13. PubMed ID: 2554602
[TBL] [Abstract][Full Text] [Related]
13. Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen.
Tamura M; Yoo YC; Yoshimatsu K; Yoshida R; Oka T; Ohkuma K; Arikawa J; Azuma I
Vaccine; 1995 Jan; 13(1):77-82. PubMed ID: 7762283
[TBL] [Abstract][Full Text] [Related]
14. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
[TBL] [Abstract][Full Text] [Related]
15. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of non-specific resistance to infection by muroctasin.
Otani T; Une T; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
[TBL] [Abstract][Full Text] [Related]
17. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.
Azuma I
Vaccine; 1992; 10(14):1000-6. PubMed ID: 1471423
[TBL] [Abstract][Full Text] [Related]
18. Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo.
Effenberg R; Turánek Knötigová P; Zyka D; Čelechovská H; Mašek J; Bartheldyová E; Hubatka F; Koudelka Š; Lukáč R; Kovalová A; Šaman D; Křupka M; Barkocziova L; Kosztyu P; Šebela M; Drož L; Hučko M; Kanásová M; Miller AD; Raška M; Ledvina M; Turánek J
J Med Chem; 2017 Sep; 60(18):7745-7763. PubMed ID: 28829599
[TBL] [Abstract][Full Text] [Related]
19. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
Nagao S; Sato K; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog.
Osada Y; Mitsuyama M; Matsumoto K; Une T; Otani T; Ogawa H; Nomoto K
Infect Immun; 1982 Sep; 37(3):1285-8. PubMed ID: 6752024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
